<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600886</url>
  </required_header>
  <id_info>
    <org_study_id>CSOM230C2305</org_study_id>
    <secondary_id>2007-001972-36</secondary_id>
    <nct_id>NCT00600886</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly</brief_title>
  <official_title>A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The patients received either Pasireotide LAR or Octreotide LAR for one year of treatment.

      The objective of this study was to compare the proportion of patients with a reduction of
      mean GH level to &lt;2.5 µg/L and the normalization of IGF-1 to within normal limits (age and
      sex related) between the two treatment groups (pasireotide LAR and octreotide LAR) at 12
      months.

      Following one year of treatment patients could proceed into the study extension.

      Patients who did not respond to the treatment they were randomized to (based on month 12
      assessment results) were switched to the other treatment arm at month 13.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 11, 2008</start_date>
  <completion_date type="Actual">March 11, 2016</completion_date>
  <primary_completion_date type="Actual">March 11, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Reduction of Mean GH Level to &lt;2.5 μg/L and the Normalization of IGF-1</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of participants with a reduction of mean GH levels to &lt;2.5μg/L (based on a 5-point 2-hour profile) and normalization of sex- and age-adjusted IGF-1.
Post surgery = patients with prior surgery but no previous medical treatment for acromegaly De novo = patients with de novo disease who refused pituitary surgery or for whom pituitary surgery was contraindicated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Reduction of Mean GH Level to &lt; 2.5μg/L</measure>
    <time_frame>12 Months</time_frame>
    <description>Percentage of participants with a reduction of mean GH levels to &lt; 2.5μg/L (based on a 5-point 2-hour profile).
Post surgery = patients with prior surgery but no previous medical treatment for acromegaly De novo = patients with de novo disease who refused pituitary surgery or for whom pituitary surgery was contraindicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tumor Volume at 12 Months</measure>
    <time_frame>Baseline, 12 Months</time_frame>
    <description>Absolute and percentage change from baseline in tumor volume (assessed by pituitary MRI) Post surgery = patients with prior surgery but no previous medical treatment for acromegaly De novo = patients with de novo disease who refused pituitary surgery or for whom pituitary surgery was contraindicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Normalization of IGF-1</measure>
    <time_frame>12 Months</time_frame>
    <description>Percentage of participants with normalization of sex- and age-adjusted IGF-1. Post surgery = patients with prior surgery but no previous medical treatment for acromegaly De novo = patients with de novo disease who refused pituitary surgery or for whom pituitary surgery was contraindicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Reduction of Mean GH Level to &lt; 2.5μg/L and Normalization of IGF-1</measure>
    <time_frame>Months 3, 6, 9, 12, 16, 19, 22, 25</time_frame>
    <description>Percentage of participants with a reduction of mean GH levels to &lt; 2.5μg/L (based on a 5-point 2-hour profile) and normalization of sex- and age-adjusted IGF-1.
Denominator for time points up to Month 12 is the Full Analysis Set (FAS). Denominator for time points after Month 12 excludes patients who completed the core and did not enter the extension. Patients who discontinued were considered non-responders for the time points after discontinuation, patients who crossed over were considered non-responders for all time points after crossover. Analysis was based on data up to crossover (i.e., included data from both blinded core &amp; ext. phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Mean GH Values</measure>
    <time_frame>Baseline, Months 3, 6, 9, 12, 16, 19, 22, 25</time_frame>
    <description>Mean GH levels (based on a 5-point profile over 2 hours). Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Response for Patients Achieving a Reduction of Mean GH Level to &lt; 2.5 μg/L and Normalization of IGF-1 (No. of Responders: Pasireotite LAR = 81, Octreotide LAR = 63) )</measure>
    <time_frame>Up to 26 months</time_frame>
    <description>Time to first response for patients achieving a reduction of mean GH level to &lt; 2.5 μg/L and normalization of IGF-1. Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity Scores of Acromegaly Symptoms</measure>
    <time_frame>Baseline, Months 12, 25</time_frame>
    <description>Severity scores of acromegaly symptoms (Headache, Fatigue, Perspiration, Paresthesias, Osteoarthralgia). Symptoms were scored from 0 (no symptom) to 4 (very severe). Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ring Size</measure>
    <time_frame>Baseline, Months 12, 25</time_frame>
    <description>Ring size (based on jeweler's finger gauge). Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality-of-life as Measured by the AcroQoL Questionnaire</measure>
    <time_frame>Baseline, Months 12, 25</time_frame>
    <description>Acromegalyy quality of life (AcroQoL) total scores. The AcroQoL questionnaire is unidimensional and contains 22 items divided in two scales: one that evaluates physical aspects (eight items) and another one that evaluates psychological aspects (14 items). The scoring of the questionnaire was performed as specified by the instrument developers. Total scores range from 0 to 100. Higher scores represent better quality of life. Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Prolactin Levels</measure>
    <time_frame>Baseline, Months 12, 25</time_frame>
    <description>Prolactin Levels. Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response for Patients Achieving a Reduction of Mean GH Level to &lt;2.5 μg/L and the Normalization of IGF-1 at Month 12 (No. of Responders: Pasireotide LAR = 51, Octreotide LAR = 32)</measure>
    <time_frame>Up to 26 months</time_frame>
    <description>The duration of response is defined as the time from the date that patient first met and maintained the response criteria based on primary efficacy variable to the date that patient lost response status.
Median and corresponding 95% CI are derived based on Kaplan-Meier method. Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pasireotide Trough Concentrations by Incident Dose</measure>
    <time_frame>Months 1 - 12</time_frame>
    <description>Pasireotide LAR trough concentrations by incident dose (last dose administered prior to PK sample collection). PK observations with missing concentrations, missing dose, missing elapsed time or an elapsed time from previous injection outside of 28±2 days window were excluded.
5 patients with evaluable PK data in the pasireotide arm received erroneously 20 mg pasireotide LAR at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Octreotide Trough Concentrations by Incident Dose</measure>
    <time_frame>Months 1 - 12</time_frame>
    <description>Octreotide LAR trough concentrations by incident dose (last dose administered prior to PK sample collection). PK observations with missing concentrations, missing dose, missing elapsed time or an elapsed time from previous injection outside of 28±2 days window were excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Reduction of Mean GH Level to &lt; 2.5μg/L and Normalization of IGF-1 After Crossover</measure>
    <time_frame>Months 3, 6, 9, 12 after crossover</time_frame>
    <description>Percentage of participants with a reduction of mean GH levels to &lt; 2.5μg/L (based on a 5-point 2-hour profile) and normalization of sex- and age-adjusted IGF-1. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). Denominator for all time points is the Crossover Analysis Set (CAS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Reduction of Mean GH Level to &lt; 2.5μg/L</measure>
    <time_frame>Months 3, 6, 9, 12, 16, 19, 22, 25</time_frame>
    <description>Percentage of participants with a reduction of mean GH levels to &lt; 2.5μg/L (based on a 5-point 2-hour profile).
Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included). Denominator for time points up to Month 12 is the Full Analysis Set. Denominator for time points after Month 12 excludes patients who completed the core and did not enter the extension. Patients who discontinued were considered non-responders for the time points after discontinuation, patients who crossed over were considered non-responders for all time points after crossover.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Normalization of IGF-1</measure>
    <time_frame>Months 3, 6, 9, 12, 16, 19, 22, 25</time_frame>
    <description>Percentage of participants with normalization of sex- and age-adjusted IGF-1. Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included). Denominator for time points up to Month 12 is the FAS. Denominator for time points after Month 12 excludes patients who completed the core and did not enter the extension. Patients who discontinued were considered non-responders for the time points after discontinuation, patients who crossed over were considered non-responders for all time points after crossover.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tumor Volume</measure>
    <time_frame>Baseline, months 6, 12, 19, 25</time_frame>
    <description>Percentage change from baseline in tumor volume (assessed by pituitary MRI). Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Reduction of Mean GH Level to &lt; 2.5μg/L After Crossover</measure>
    <time_frame>Months 3, 6, 9, 12 after crossover</time_frame>
    <description>Percentage of participants with a reduction of mean GH levels to &lt; 2.5μg/L (based on a 5-point 2-hour profile). Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). Denominator for all time points is the Crossover Analysis Set (CAS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Normalization of IGF-1 After Crossover</measure>
    <time_frame>Months 3, 6, 9, 12 after crossover</time_frame>
    <description>Percentage of participants with normalization of sex- and age-adjusted IGF-1. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). Denominator for all time points is the Crossover Analysis Set (CAS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Mean GH Values After Crossover</measure>
    <time_frame>Extension baseline, months 3, 6, 9, 12 after crossover</time_frame>
    <description>Mean GH levels (based on a 5-point profile over 2 hours). Extension baseline was defined as last measurement prior to the start of crossover treatment. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Extension Baseline in Tumor Volume After Crossover</measure>
    <time_frame>Extension baseline, months 6, 12 after crossover</time_frame>
    <description>Percentage change from extension baseline in tumor volume (assessed by pituitary MRI).
Extension baseline was defined as last assessment prior to the administration of the new treatment after crossover. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity Scores of Acromegaly Symptoms After Crossover</measure>
    <time_frame>Extension baseline, month 12 after crossover</time_frame>
    <description>Severity scores of acromegaly symptoms (Headache, Fatigue, Perspiration, Paresthesias, Osteoarthralgia).
Symptoms were scored from 0 (no symptom) to 4 (very severe). Extension baseline was defined as last measurement prior to the start of crossover treatment. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ring Size After Crossover</measure>
    <time_frame>Extension baseline, month 12 after crossover</time_frame>
    <description>Ring size (based on jeweler's finger gauge). Extension baseline was defined as last measurement prior to the start of crossover treatment. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). BL = baseline, LH = left hand, RH = right hand, CO = crossover</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality-of-life as Measured by the AcroQoL Questionnaire After Crossover</measure>
    <time_frame>Extension baseline, months 12 after crossover</time_frame>
    <description>AcroQoL total scores. The AcroQoL questionnaire is unidimensional and contains 22 items divided in two scales: one that evaluates physical aspects (eight items) and another one that evaluates psychological aspects (14 items). The scoring of the questionnaire was performed as specified by the instrument developers. Extension baseline was defined as last measurement prior to the start of crossover treatment. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). Total scores range from 0 to 100. Higher scores represent better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Prolactin Levels After Crossover</measure>
    <time_frame>Extension baseline, month 12 after crossover</time_frame>
    <description>Prolactin (PRL) levels. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). Extension baseline was defined as last measurement prior to the start of crossover treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">358</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>Pasireotide LAR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm received Pasireotide LAR 40 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 20 or 60 mg, respectively. Patients who responded to Pasireotide LAR (i.e. the randomized treatment) at the end of the core (Month 12), continued Pasireotide LAR treatment in the extension. Patients who did not respond to Pasireotide LAR at the end of the core (Month 12) were allowed to switch to receive Octreotide LAR in the extension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Octreotide LAR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm received Octreotide LAR 20 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 10 or 30 mg, respectively. Patients who responded to Octreotide LAR (i.e. the randomized treatment) at the end of the core (Month 12) continued Octreotide LAR treatment in the extension (up to 2 years of treatment). Patients who did not respond to Octreotide LAR at the end of the core (Month 12) were allowed to switch to receive Pasireotide LAR in the extension.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pasireotide</intervention_name>
    <description>Pasireotide LAR - intramuscular (i.m.) depot injection given once every 28 days.</description>
    <arm_group_label>Pasireotide LAR</arm_group_label>
    <other_name>SOM230</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide</intervention_name>
    <description>Octreotide LAR - i.m. depot injection given once every 28 days.</description>
    <arm_group_label>Octreotide LAR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with active acromegaly (based on elevated GH and IGF-1 levels)

          -  Patients who have undergone one or more pituitary surgeries, but have not been treated
             medically, or de-novo patients presenting a visible pituitary adenoma on MRI and who
             refuse pituitary surgery or for whom pituitary surgery is contraindicated

          -  Patients for whom written informed consent to participate in the study has been
             obtained prior to any study related activity

        Exclusion criteria:

          -  Patients who are being or were treated with octreotide, lanreotide, dopamine agonists
             or GH antagonists with the exception of a single dose of short-acting octrotide or
             short-acting dopamine agonists. In case of a single dose of short-acting octrotide,
             the dose should not be used to predict the response to the octretide treatment. The
             single dose of short-acting octreotide or short-acting dopamine agonists should not be
             administered in the 3 days prior to randomization

          -  Patients with compression of the optic chiasm causing any visual field defect

          -  Patients who have received pituitary irradiation within the last ten years prior to
             visit 1

          -  Poorly controlled diabetic patients

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center The Pituitary Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at Los Angeles Division of Endocrinology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center Stanford Cancer Center (3)</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida SC</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine Dept.ofJohnsHopkinsUniv.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center Deptof Endocrinology&amp;Diabetes</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0944</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center- New York Presbyterian Dept. of CU Collegeof Phys&amp;Sur</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northport VA Medical Center CSOM230C2305</name>
      <address>
        <city>Northport</city>
        <state>New York</state>
        <zip>11768</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Sciences University DeptofOregonHealth&amp;Sciences(3)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Endocrinology Associates</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center Danziger Research Bldg.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson Cancer Center Regulatory -12</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center Dept.ofSeattle Neuroscience(2)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1405BCH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>1425EKP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1232AAC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fortaleza</city>
        <state>CE</state>
        <zip>60430 370</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brasilia</city>
        <state>DF</state>
        <zip>70840-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Luis</city>
        <state>MA</state>
        <zip>65020-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21941-913</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 2W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>111411</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague 2</city>
        <state>Czech republic</state>
        <zip>128 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aalborg</city>
        <zip>DK-9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bois Guillaume Cedex</city>
        <zip>76233</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille cedex 05</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pessac Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <state>GR</state>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pireas</city>
        <zip>18537</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cona</city>
        <state>FE</state>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>130-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>México</city>
        <state>Distrito Federal</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergen</city>
        <zip>NO-5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>NO-0379</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-531</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01 809</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linkoping</city>
        <zip>SE-581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malmö</city>
        <zip>SE-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lin-Kou</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erzurum</city>
        <zip>25240</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Czech Republic</country>
    <country>Portugal</country>
    <country>Venezuela</country>
  </removed_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2008</study_first_submitted>
  <study_first_submitted_qc>January 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2008</study_first_posted>
  <results_first_submitted>December 19, 2014</results_first_submitted>
  <results_first_submitted_qc>January 28, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2015</results_first_posted>
  <disposition_first_submitted>November 4, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>November 4, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 18, 2014</disposition_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acromegaly,</keyword>
  <keyword>adult,</keyword>
  <keyword>growth hormone,</keyword>
  <keyword>insulin-like growth factor I,</keyword>
  <keyword>somatostatin analogue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Pasireotide</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pasireotide LAR</title>
          <description>Patients in this arm received Pasireotide LAR 40 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 20 or 60 mg, respectively. Patients who responded to Pasireotide LAR (i.e. the randomized treatment) at the end of the core (Month 12), continued Pasireotide LAR treatment in the extension. Patients who did not respond to Pasireotide LAR at the end of the core (Month 12) were allowed to switch to receive Octreotide LAR in the extension.</description>
        </group>
        <group group_id="P2">
          <title>Octreotide LAR</title>
          <description>Patients in this arm received Octreotide LAR 20 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 10 or 30 mg, respectively. Patients who responded to Octreotide LAR (i.e. the randomized treatment) at the end of the core (Month 12) continued Octreotide LAR treatment in the extension (up to 2 years of treatment). Patients who did not respond to Octreotide LAR at the end of the core (Month 12) were allowed to switch to receive Pasireotide LAR in the extension.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Core Phase - Full Analysis Set (FAS)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="182"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Did Not Enter Extension</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered Extension, Crossed Over</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered Ext Continued Same Treatment</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="141">Completed = anyone who did not discontinue prior to month 12.</participants>
                <participants group_id="P2" count="156">Completed = anyone who did not discontinue prior to month 12.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Problems</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value(s)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension - Same Treatment (FAS)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74">Started = anyone who entered the extension and continued the same treatment of Pasireotide LAR</participants>
                <participants group_id="P2" count="46">Started = anyone who entered the extension and continued the same treatment of Octreotide LAR</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Study at Month 26</title>
              <participants_list>
                <participants group_id="P1" count="0">Pas. LAR pts in Ext. were not considered completers at M26 as treatment could continue after M26.</participants>
                <participants group_id="P2" count="31">Per protocol, pts who received Octreotide LAR in ext. phase were not followed in the study after M26</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Study After Month 26</title>
              <participants_list>
                <participants group_id="P1" count="28">Completed = Pts who transferred to a roll-over protocol or commercial supply of Pasireotide LAR</participants>
                <participants group_id="P2" count="4">Received treatment and completed after M26: Recorded as protocol deviation</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued After Month 26</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="1">Received treatment and discontinued after M26: Recorded as protocol deviation</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued Between M12 and M26</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28">Completed= completed after M26, switched to commercial pasireotide LAR or entered roll-over protocol</participants>
                <participants group_id="P2" count="35">Completed = completed the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Problems</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Lab Value (s)</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Condition no longer requires study drug</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension - After Crossover (CAS)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81">Started = anyone who entered the extension and crossed over to Pasireotide LAR</participants>
                <participants group_id="P2" count="38">Started = anyone who entered the extension and crossed over to Octreotide LAR</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Study at Month 26</title>
              <participants_list>
                <participants group_id="P1" count="0">Pas. LAR pts in Ext. were not considered completers at M26 as treatment could continue after M26.</participants>
                <participants group_id="P2" count="25">Per protocol, Pts who received Octreotide LAR in Ext. phase were not followed in study after M26</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed After Month 26</title>
              <participants_list>
                <participants group_id="P1" count="19">Completed = Pts who transferred to a roll-over protocol or commercial supply of Pasireotide LAR</participants>
                <participants group_id="P2" count="0">Per protocol, pts who received Octreotide LAR in ext. phase were not followed in study after M26</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued Between M12 and M26</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued After M26</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="0">Per protocol, Pts who received Octreotide LAR in Ext. phase were not followed in study after M26</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19">Completed after month 26: transferred to a roll-over protocol or commercial supply of Pas.LAR</participants>
                <participants group_id="P2" count="25">Completed the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Problems</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject no longer requires study drug</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Lab Value (s)</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set: All patients who were randomized into the study. Patients were analyzed according to the treatment they were assigned to at randomization.</population>
      <group_list>
        <group group_id="B1">
          <title>Pasireotide LAR</title>
          <description>Patients in this arm received Pasireotide LAR 40 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 20 or 60 mg, respectively. Patients who responded to Pasireotide LAR (i.e. the randomized treatment) at the end of the core (Month 12), continued Pasireotide LAR treatment in the extension. Patients who did not respond to Pasireotide LAR at the end of the core (Month 12) were allowed to switch to receive Octreotide LAR in the extension.</description>
        </group>
        <group group_id="B2">
          <title>Octreotide LAR</title>
          <description>Patients in this arm received Octreotide LAR 20 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 10 or 30 mg, respectively. Patients who responded to Octreotide LAR (i.e. the randomized treatment) at the end of the core (Month 12) continued Octreotide LAR treatment in the extension (up to 2 years of treatment). Patients who did not respond to Octreotide LAR at the end of the core (Month 12) were allowed to switch to receive Pasireotide LAR in the extension.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="176"/>
            <count group_id="B2" value="182"/>
            <count group_id="B3" value="358"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.1" spread="12.37"/>
                    <measurement group_id="B2" value="45.6" spread="12.97"/>
                    <measurement group_id="B3" value="45.4" spread="12.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="186"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Reduction of Mean GH Level to &lt;2.5 μg/L and the Normalization of IGF-1</title>
        <description>Percentage of participants with a reduction of mean GH levels to &lt;2.5μg/L (based on a 5-point 2-hour profile) and normalization of sex- and age-adjusted IGF-1.
Post surgery = patients with prior surgery but no previous medical treatment for acromegaly De novo = patients with de novo disease who refused pituitary surgery or for whom pituitary surgery was contraindicated.</description>
        <time_frame>12 months</time_frame>
        <population>Full Analysis Set: All patients (Pts) who were randomized into the study. Pts were analyzed according to the treatment they were assigned to at randomization. Missing mean GH and/or IGF-1 levels at M12 were imputed using data obtained at or after M6 by the last observation carried forward method; otherwise, Pts were considered as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR (Core)</title>
            <description>Includes data from the 12-month blinded core phase for patients randomized to receive Pasireotide LAR.</description>
          </group>
          <group group_id="O2">
            <title>Octreotide LAR (Core)</title>
            <description>Includes data from the 12-month blinded core phase for patients randomized to receive Octreotide LAR.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Reduction of Mean GH Level to &lt;2.5 μg/L and the Normalization of IGF-1</title>
          <description>Percentage of participants with a reduction of mean GH levels to &lt;2.5μg/L (based on a 5-point 2-hour profile) and normalization of sex- and age-adjusted IGF-1.
Post surgery = patients with prior surgery but no previous medical treatment for acromegaly De novo = patients with de novo disease who refused pituitary surgery or for whom pituitary surgery was contraindicated.</description>
          <population>Full Analysis Set: All patients (Pts) who were randomized into the study. Pts were analyzed according to the treatment they were assigned to at randomization. Missing mean GH and/or IGF-1 levels at M12 were imputed using data obtained at or after M6 by the last observation carried forward method; otherwise, Pts were considered as non-responders.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" lower_limit="24.5" upper_limit="38.7"/>
                    <measurement group_id="O2" value="19.2" lower_limit="13.8" upper_limit="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.4" lower_limit="28.0" upper_limit="51.7"/>
                    <measurement group_id="O2" value="21.8" lower_limit="13.2" upper_limit="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>De novo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7" lower_limit="17.7" upper_limit="35.2"/>
                    <measurement group_id="O2" value="17.3" lower_limit="10.6" upper_limit="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Overall - All patients</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel adjusting for randomization stratification factor</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.942</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.190</ci_lower_limit>
            <ci_upper_limit>3.168</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Post surgery - patients with prior surgery but no previous medical treatment for acromegaly</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.337</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.140</ci_lower_limit>
            <ci_upper_limit>4.790</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>De novo - patients with de novo disease who refused pituitary surgery or for whom pituitary surgery was contraindicated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.654</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.846</ci_lower_limit>
            <ci_upper_limit>3.234</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Reduction of Mean GH Level to &lt; 2.5μg/L</title>
        <description>Percentage of participants with a reduction of mean GH levels to &lt; 2.5μg/L (based on a 5-point 2-hour profile).
Post surgery = patients with prior surgery but no previous medical treatment for acromegaly De novo = patients with de novo disease who refused pituitary surgery or for whom pituitary surgery was contraindicated.</description>
        <time_frame>12 Months</time_frame>
        <population>FAS: All patients (Pts) who were randomized into the study. Pts were analyzed according to the treatment they were assigned to at randomization. Missing mean GH levels at Month 12 were imputed using data obtained at or after Month 6 by the LOCF (last observation carried forward) method; otherwise, Pts were considered as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR (Core)</title>
            <description>Includes data from the 12-month blinded core phase for patients randomized to receive Pasireotide LAR.</description>
          </group>
          <group group_id="O2">
            <title>Octreotide LAR (Core)</title>
            <description>Includes data from the 12-month blinded core phase for patients randomized to receive Octreotide LAR.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Reduction of Mean GH Level to &lt; 2.5μg/L</title>
          <description>Percentage of participants with a reduction of mean GH levels to &lt; 2.5μg/L (based on a 5-point 2-hour profile).
Post surgery = patients with prior surgery but no previous medical treatment for acromegaly De novo = patients with de novo disease who refused pituitary surgery or for whom pituitary surgery was contraindicated.</description>
          <population>FAS: All patients (Pts) who were randomized into the study. Pts were analyzed according to the treatment they were assigned to at randomization. Missing mean GH levels at Month 12 were imputed using data obtained at or after Month 6 by the LOCF (last observation carried forward) method; otherwise, Pts were considered as non-responders.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3" lower_limit="40.7" upper_limit="55.9"/>
                    <measurement group_id="O2" value="51.6" lower_limit="44.1" upper_limit="59.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.1" lower_limit="39.9" upper_limit="64.1"/>
                    <measurement group_id="O2" value="51.3" lower_limit="39.7" upper_limit="62.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>De novo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7" lower_limit="36.0" upper_limit="55.7"/>
                    <measurement group_id="O2" value="51.9" lower_limit="41.9" upper_limit="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tumor Volume at 12 Months</title>
        <description>Absolute and percentage change from baseline in tumor volume (assessed by pituitary MRI) Post surgery = patients with prior surgery but no previous medical treatment for acromegaly De novo = patients with de novo disease who refused pituitary surgery or for whom pituitary surgery was contraindicated.</description>
        <time_frame>Baseline, 12 Months</time_frame>
        <population>Full Analysis Set (FAS): All patients who were randomized into the study. Patients were analyzed according to the treatment they were assigned to at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR (Core)</title>
            <description>Includes data from the 12-month blinded core phase for patients randomized to receive Pasireotide LAR.</description>
          </group>
          <group group_id="O2">
            <title>Octreotide LAR (Core)</title>
            <description>Includes data from the 12-month blinded core phase for patients randomized to receive Octreotide LAR.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tumor Volume at 12 Months</title>
          <description>Absolute and percentage change from baseline in tumor volume (assessed by pituitary MRI) Post surgery = patients with prior surgery but no previous medical treatment for acromegaly De novo = patients with de novo disease who refused pituitary surgery or for whom pituitary surgery was contraindicated.</description>
          <population>Full Analysis Set (FAS): All patients who were randomized into the study. Patients were analyzed according to the treatment they were assigned to at randomization.</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2420.7" spread="4159.21"/>
                    <measurement group_id="O2" value="2259.2" spread="3390.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall % change at month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.7" spread="21.83"/>
                    <measurement group_id="O2" value="-38.0" spread="24.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post surgery at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2185.2" spread="2861.09"/>
                    <measurement group_id="O2" value="2196.5" spread="3922.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post surgery % change at month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.5" spread="20.60"/>
                    <measurement group_id="O2" value="-39.0" spread="23.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>De novo at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2592.4" spread="4901.99"/>
                    <measurement group_id="O2" value="2308.1" spread="2930.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>De novo % change at month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.9" spread="22.65"/>
                    <measurement group_id="O2" value="-37.2" spread="25.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall absolute change at month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="128"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-987.1" spread="2448.14"/>
                    <measurement group_id="O2" value="-801.2" spread="1676.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post surgery abs. change at month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-873.7" spread="1282.06"/>
                    <measurement group_id="O2" value="-713.8" spread="1708.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>De novo absolute change at month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1051.9" spread="2919.18"/>
                    <measurement group_id="O2" value="-867.1" spread="1661.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Normalization of IGF-1</title>
        <description>Percentage of participants with normalization of sex- and age-adjusted IGF-1. Post surgery = patients with prior surgery but no previous medical treatment for acromegaly De novo = patients with de novo disease who refused pituitary surgery or for whom pituitary surgery was contraindicated.</description>
        <time_frame>12 Months</time_frame>
        <population>Full Analysis Set: All patients (Pts) who were randomized into the study. Pts were analyzed according to the treatment they were assigned to at randomization. Missing IGF-1 levels at Month 12 were imputed using data obtained at or after Month 6 by the LOCF (last observation carried forward) method; otherwise, Pts were considered as nonresponders.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR (Core)</title>
            <description>Includes data from the 12-month blinded core phase for patients randomized to receive Pasireotide LAR.</description>
          </group>
          <group group_id="O2">
            <title>Octreotide LAR (Core)</title>
            <description>Includes data from the 12-month blinded core phase for patients randomized to receive Octreotide LAR.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Normalization of IGF-1</title>
          <description>Percentage of participants with normalization of sex- and age-adjusted IGF-1. Post surgery = patients with prior surgery but no previous medical treatment for acromegaly De novo = patients with de novo disease who refused pituitary surgery or for whom pituitary surgery was contraindicated.</description>
          <population>Full Analysis Set: All patients (Pts) who were randomized into the study. Pts were analyzed according to the treatment they were assigned to at randomization. Missing IGF-1 levels at Month 12 were imputed using data obtained at or after Month 6 by the LOCF (last observation carried forward) method; otherwise, Pts were considered as nonresponders.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6" lower_limit="31.4" upper_limit="46.3"/>
                    <measurement group_id="O2" value="23.6" lower_limit="17.7" upper_limit="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.7" lower_limit="38.6" upper_limit="62.8"/>
                    <measurement group_id="O2" value="26.9" lower_limit="17.5" upper_limit="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>De novo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" lower_limit="21.9" upper_limit="40.2"/>
                    <measurement group_id="O2" value="21.2" lower_limit="13.8" upper_limit="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Reduction of Mean GH Level to &lt; 2.5μg/L and Normalization of IGF-1</title>
        <description>Percentage of participants with a reduction of mean GH levels to &lt; 2.5μg/L (based on a 5-point 2-hour profile) and normalization of sex- and age-adjusted IGF-1.
Denominator for time points up to Month 12 is the Full Analysis Set (FAS). Denominator for time points after Month 12 excludes patients who completed the core and did not enter the extension. Patients who discontinued were considered non-responders for the time points after discontinuation, patients who crossed over were considered non-responders for all time points after crossover. Analysis was based on data up to crossover (i.e., included data from both blinded core &amp; ext. phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included.)</description>
        <time_frame>Months 3, 6, 9, 12, 16, 19, 22, 25</time_frame>
        <population>Full Analysis Set: All patients who were randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Pasireotide LAR) as in the core. For patients who switched from blinded Pasireotide LAR to Octreotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
          <group group_id="O2">
            <title>Octreotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Octreotide LAR) as in the core. For patients who switched from blinded Octreotide LAR to Pasireotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Reduction of Mean GH Level to &lt; 2.5μg/L and Normalization of IGF-1</title>
          <description>Percentage of participants with a reduction of mean GH levels to &lt; 2.5μg/L (based on a 5-point 2-hour profile) and normalization of sex- and age-adjusted IGF-1.
Denominator for time points up to Month 12 is the Full Analysis Set (FAS). Denominator for time points after Month 12 excludes patients who completed the core and did not enter the extension. Patients who discontinued were considered non-responders for the time points after discontinuation, patients who crossed over were considered non-responders for all time points after crossover. Analysis was based on data up to crossover (i.e., included data from both blinded core &amp; ext. phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included.)</description>
          <population>Full Analysis Set: All patients who were randomized into the study.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" lower_limit="23.4" upper_limit="37.5"/>
                    <measurement group_id="O2" value="21.4" lower_limit="15.7" upper_limit="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" lower_limit="23.4" upper_limit="37.5"/>
                    <measurement group_id="O2" value="19.8" lower_limit="14.3" upper_limit="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" lower_limit="21.4" upper_limit="35.1"/>
                    <measurement group_id="O2" value="23.1" lower_limit="17.2" upper_limit="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" lower_limit="22.4" upper_limit="36.3"/>
                    <measurement group_id="O2" value="17.6" lower_limit="12.3" upper_limit="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" lower_limit="18.4" upper_limit="33.0"/>
                    <measurement group_id="O2" value="12.4" lower_limit="7.6" upper_limit="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" lower_limit="16.6" upper_limit="30.8"/>
                    <measurement group_id="O2" value="13.7" lower_limit="8.7" upper_limit="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" lower_limit="18.4" upper_limit="33.0"/>
                    <measurement group_id="O2" value="16.3" lower_limit="10.9" upper_limit="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" lower_limit="17.8" upper_limit="32.3"/>
                    <measurement group_id="O2" value="13.7" lower_limit="8.7" upper_limit="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Mean GH Values</title>
        <description>Mean GH levels (based on a 5-point profile over 2 hours). Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
        <time_frame>Baseline, Months 3, 6, 9, 12, 16, 19, 22, 25</time_frame>
        <population>Full Analysis Set: All patients who were randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Pasireotide LAR) as in the core. For patients who switched from blinded Pasireotide LAR to Octreotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
          <group group_id="O2">
            <title>Octreotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Octreotide LAR) as in the core. For patients who switched from blinded Octreotide LAR to Pasireotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Mean GH Values</title>
          <description>Mean GH levels (based on a 5-point profile over 2 hours). Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
          <population>Full Analysis Set: All patients who were randomized into the study.</population>
          <units>μg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="167"/>
                    <count group_id="O2" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" spread="32.14"/>
                    <measurement group_id="O2" value="18.8" spread="25.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="12.54"/>
                    <measurement group_id="O2" value="5.8" spread="12.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="151"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="11.47"/>
                    <measurement group_id="O2" value="5.2" spread="10.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="9.62"/>
                    <measurement group_id="O2" value="4.3" spread="9.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="9.51"/>
                    <measurement group_id="O2" value="4.5" spread="11.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="5.64"/>
                    <measurement group_id="O2" value="1.4" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="5.68"/>
                    <measurement group_id="O2" value="1.5" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="6.15"/>
                    <measurement group_id="O2" value="1.4" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="5.02"/>
                    <measurement group_id="O2" value="1.2" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Response for Patients Achieving a Reduction of Mean GH Level to &lt; 2.5 μg/L and Normalization of IGF-1 (No. of Responders: Pasireotite LAR = 81, Octreotide LAR = 63) )</title>
        <description>Time to first response for patients achieving a reduction of mean GH level to &lt; 2.5 μg/L and normalization of IGF-1. Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
        <time_frame>Up to 26 months</time_frame>
        <population>Full Analysis Set: All patients who were randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Pasireotide LAR) as in the core. For patients who switched from blinded Pasireotide LAR to Octreotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
          <group group_id="O2">
            <title>Octreotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Octreotide LAR) as in the core. For patients who switched from blinded Octreotide LAR to Pasireotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Response for Patients Achieving a Reduction of Mean GH Level to &lt; 2.5 μg/L and Normalization of IGF-1 (No. of Responders: Pasireotite LAR = 81, Octreotide LAR = 63) )</title>
          <description>Time to first response for patients achieving a reduction of mean GH level to &lt; 2.5 μg/L and normalization of IGF-1. Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
          <population>Full Analysis Set: All patients who were randomized into the study.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" lower_limit="12.3" upper_limit="13.0"/>
                    <measurement group_id="O2" value="12.4" lower_limit="12.3" upper_limit="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity Scores of Acromegaly Symptoms</title>
        <description>Severity scores of acromegaly symptoms (Headache, Fatigue, Perspiration, Paresthesias, Osteoarthralgia). Symptoms were scored from 0 (no symptom) to 4 (very severe). Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
        <time_frame>Baseline, Months 12, 25</time_frame>
        <population>Full Analysis Set: All patients who were randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Pasireotide LAR) as in the core. For patients who switched from blinded Pasireotide LAR to Octreotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
          <group group_id="O2">
            <title>Octreotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Octreotide LAR) as in the core. For patients who switched from blinded Octreotide LAR to Pasireotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
        </group_list>
        <measure>
          <title>Severity Scores of Acromegaly Symptoms</title>
          <description>Severity scores of acromegaly symptoms (Headache, Fatigue, Perspiration, Paresthesias, Osteoarthralgia). Symptoms were scored from 0 (no symptom) to 4 (very severe). Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
          <population>Full Analysis Set: All patients who were randomized into the study.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Headache - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.05"/>
                    <measurement group_id="O2" value="1.0" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.13"/>
                    <measurement group_id="O2" value="1.4" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Perspiration - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.21"/>
                    <measurement group_id="O2" value="1.3" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paresthesia - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.00"/>
                    <measurement group_id="O2" value="0.8" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteoarthraliga - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.05"/>
                    <measurement group_id="O2" value="1.3" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache - M12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.77"/>
                    <measurement group_id="O2" value="0.6" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue - M12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.95"/>
                    <measurement group_id="O2" value="0.7" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Perspiration - M12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.81"/>
                    <measurement group_id="O2" value="0.5" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paresthesia - M12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.63"/>
                    <measurement group_id="O2" value="0.4" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteoarthraliga - M12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.80"/>
                    <measurement group_id="O2" value="0.7" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache - M25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.61"/>
                    <measurement group_id="O2" value="0.6" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue - M25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.71"/>
                    <measurement group_id="O2" value="0.7" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Perspiration - M25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.72"/>
                    <measurement group_id="O2" value="0.4" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paresthesia - M25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.49"/>
                    <measurement group_id="O2" value="0.4" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteoarthraliga - M25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.79"/>
                    <measurement group_id="O2" value="0.8" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ring Size</title>
        <description>Ring size (based on jeweler’s finger gauge). Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
        <time_frame>Baseline, Months 12, 25</time_frame>
        <population>Full Analysis Set: All patients who were randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Pasireotide LAR) as in the core. For patients who switched from blinded Pasireotide LAR to Octreotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
          <group group_id="O2">
            <title>Octreotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Octreotide LAR) as in the core. For patients who switched from blinded Octreotide LAR to Pasireotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
        </group_list>
        <measure>
          <title>Ring Size</title>
          <description>Ring size (based on jeweler’s finger gauge). Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
          <population>Full Analysis Set: All patients who were randomized into the study.</population>
          <units>ring zize</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline left hand (LH) 4th digit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="2.00"/>
                    <measurement group_id="O2" value="11.8" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline left hand 5th digit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="2.82"/>
                    <measurement group_id="O2" value="12.4" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline right hand (RH) 4th digit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="2.01"/>
                    <measurement group_id="O2" value="11.4" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline right hand 5th digit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="3.35"/>
                    <measurement group_id="O2" value="11.3" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12 LH 4th digit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="2.05"/>
                    <measurement group_id="O2" value="11.1" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12 LH 5th digit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="1.81"/>
                    <measurement group_id="O2" value="12.4" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12 RH 4th digit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="2.12"/>
                    <measurement group_id="O2" value="11.3" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12 RH 5th digit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="3.96"/>
                    <measurement group_id="O2" value="10.5" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M25 LH 4th digit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="2.12"/>
                    <measurement group_id="O2" value="11.1" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M25 LH 5th digit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="2.45"/>
                    <measurement group_id="O2" value="14.3" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M25 RH 4th digit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="1.98"/>
                    <measurement group_id="O2" value="10.9" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M25 RH 5th digit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="4.60"/>
                    <measurement group_id="O2" value="7.5">N/A = Not applicable for Std. Dev.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality-of-life as Measured by the AcroQoL Questionnaire</title>
        <description>Acromegalyy quality of life (AcroQoL) total scores. The AcroQoL questionnaire is unidimensional and contains 22 items divided in two scales: one that evaluates physical aspects (eight items) and another one that evaluates psychological aspects (14 items). The scoring of the questionnaire was performed as specified by the instrument developers. Total scores range from 0 to 100. Higher scores represent better quality of life. Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
        <time_frame>Baseline, Months 12, 25</time_frame>
        <population>Full Analysis Set: All patients who were randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Pasireotide LAR) as in the core. For patients who switched from blinded Pasireotide LAR to Octreotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
          <group group_id="O2">
            <title>Octreotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Octreotide LAR) as in the core. For patients who switched from blinded Octreotide LAR to Pasireotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality-of-life as Measured by the AcroQoL Questionnaire</title>
          <description>Acromegalyy quality of life (AcroQoL) total scores. The AcroQoL questionnaire is unidimensional and contains 22 items divided in two scales: one that evaluates physical aspects (eight items) and another one that evaluates psychological aspects (14 items). The scoring of the questionnaire was performed as specified by the instrument developers. Total scores range from 0 to 100. Higher scores represent better quality of life. Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
          <population>Full Analysis Set: All patients who were randomized into the study.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                    <count group_id="O2" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.4" spread="19.97"/>
                    <measurement group_id="O2" value="55.6" spread="19.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.7" spread="21.64"/>
                    <measurement group_id="O2" value="61.6" spread="21.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3" spread="18.76"/>
                    <measurement group_id="O2" value="62.9" spread="18.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Prolactin Levels</title>
        <description>Prolactin Levels. Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
        <time_frame>Baseline, Months 12, 25</time_frame>
        <population>Full Analysis Set: All patients who were randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Pasireotide LAR) as in the core. For patients who switched from blinded Pasireotide LAR to Octreotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
          <group group_id="O2">
            <title>Octreotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Octreotide LAR) as in the core. For patients who switched from blinded Octreotide LAR to Pasireotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Prolactin Levels</title>
          <description>Prolactin Levels. Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
          <population>Full Analysis Set: All patients who were randomized into the study.</population>
          <units>μg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6" spread="53.00"/>
                    <measurement group_id="O2" value="15.8" spread="22.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="19.24"/>
                    <measurement group_id="O2" value="11.7" spread="19.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="4.37"/>
                    <measurement group_id="O2" value="6.7" spread="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response for Patients Achieving a Reduction of Mean GH Level to &lt;2.5 μg/L and the Normalization of IGF-1 at Month 12 (No. of Responders: Pasireotide LAR = 51, Octreotide LAR = 32)</title>
        <description>The duration of response is defined as the time from the date that patient first met and maintained the response criteria based on primary efficacy variable to the date that patient lost response status.
Median and corresponding 95% CI are derived based on Kaplan-Meier method. Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
        <time_frame>Up to 26 months</time_frame>
        <population>Full Analysis Set: All patients who were randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Pasireotide LAR) as in the core. For patients who switched from blinded Pasireotide LAR to Octreotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
          <group group_id="O2">
            <title>Octreotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Octreotide LAR) as in the core. For patients who switched from blinded Octreotide LAR to Pasireotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response for Patients Achieving a Reduction of Mean GH Level to &lt;2.5 μg/L and the Normalization of IGF-1 at Month 12 (No. of Responders: Pasireotide LAR = 51, Octreotide LAR = 32)</title>
          <description>The duration of response is defined as the time from the date that patient first met and maintained the response criteria based on primary efficacy variable to the date that patient lost response status.
Median and corresponding 95% CI are derived based on Kaplan-Meier method. Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
          <population>Full Analysis Set: All patients who were randomized into the study.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.4" lower_limit="52.1" upper_limit="100.4"/>
                    <measurement group_id="O2" value="64.6" lower_limit="40.0" upper_limit="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pasireotide Trough Concentrations by Incident Dose</title>
        <description>Pasireotide LAR trough concentrations by incident dose (last dose administered prior to PK sample collection). PK observations with missing concentrations, missing dose, missing elapsed time or an elapsed time from previous injection outside of 28±2 days window were excluded.
5 patients with evaluable PK data in the pasireotide arm received erroneously 20 mg pasireotide LAR at baseline.</description>
        <time_frame>Months 1 - 12</time_frame>
        <population>PK analysis set: All patients with at least one LAR injection and one post-dose trough concentration data in core phase (up to month 12). No participants took the 60 mg dose in Months 1, 2 and 3, hence no data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR 20 mg</title>
            <description>Patients in this arm received Pasireotide LAR 20 mg injection prior to PK sample collection.</description>
          </group>
          <group group_id="O2">
            <title>Pasireotide LAR 40 mg</title>
            <description>Patients in this arm received Pasireotide LAR 40 mg injection prior to PK sample collection.</description>
          </group>
          <group group_id="O3">
            <title>Pasireotide LAR 60mg</title>
            <description>Patients in this arm received Pasireotide LAR 60 mg injection prior to PK sample collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Pasireotide Trough Concentrations by Incident Dose</title>
          <description>Pasireotide LAR trough concentrations by incident dose (last dose administered prior to PK sample collection). PK observations with missing concentrations, missing dose, missing elapsed time or an elapsed time from previous injection outside of 28±2 days window were excluded.
5 patients with evaluable PK data in the pasireotide arm received erroneously 20 mg pasireotide LAR at baseline.</description>
          <population>PK analysis set: All patients with at least one LAR injection and one post-dose trough concentration data in core phase (up to month 12). No participants took the 60 mg dose in Months 1, 2 and 3, hence no data.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="146"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.65" spread="0.645"/>
                    <measurement group_id="O2" value="6.65" spread="3.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" spread="1.371"/>
                    <measurement group_id="O2" value="7.81" spread="3.505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" spread="2.659"/>
                    <measurement group_id="O2" value="8.70" spread="5.402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" spread="1.858"/>
                    <measurement group_id="O2" value="9.51" spread="5.487"/>
                    <measurement group_id="O3" value="13.48" spread="7.750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.22" spread="4.077"/>
                    <measurement group_id="O2" value="10.92" spread="6.017"/>
                    <measurement group_id="O3" value="13.42" spread="6.902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" spread="1.101"/>
                    <measurement group_id="O2" value="10.59" spread="6.216"/>
                    <measurement group_id="O3" value="13.08" spread="6.967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" spread="0.857"/>
                    <measurement group_id="O2" value="11.85" spread="7.781"/>
                    <measurement group_id="O3" value="14.76" spread="6.868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.65" spread="1.865"/>
                    <measurement group_id="O2" value="12.33" spread="7.619"/>
                    <measurement group_id="O3" value="15.88" spread="9.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80" spread="1.957"/>
                    <measurement group_id="O2" value="12.75" spread="8.604"/>
                    <measurement group_id="O3" value="16.03" spread="10.852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.66" spread="3.606"/>
                    <measurement group_id="O2" value="12.42" spread="7.252"/>
                    <measurement group_id="O3" value="16.01" spread="11.497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.10" spread="2.375"/>
                    <measurement group_id="O2" value="12.62" spread="6.920"/>
                    <measurement group_id="O3" value="16.31" spread="10.596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.54" spread="1.634"/>
                    <measurement group_id="O2" value="11.11" spread="6.489"/>
                    <measurement group_id="O3" value="16.16" spread="9.323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Octreotide Trough Concentrations by Incident Dose</title>
        <description>Octreotide LAR trough concentrations by incident dose (last dose administered prior to PK sample collection). PK observations with missing concentrations, missing dose, missing elapsed time or an elapsed time from previous injection outside of 28±2 days window were excluded.</description>
        <time_frame>Months 1 - 12</time_frame>
        <population>PK analysis set: All patients with at least one LAR injection and one post-dose trough concentration data in core phase (up to month 12). No participants took the 30 mg dose in Months 1, 2 and 3, hence no data.</population>
        <group_list>
          <group group_id="O1">
            <title>Octreotide LAR 10mg</title>
            <description>Patients in this arm received Octreotide LAR 10 mg injection prior to PK sample collection.</description>
          </group>
          <group group_id="O2">
            <title>Octreotide LAR 20 mg</title>
            <description>Patients in this arm received Octreotide LAR 20 mg injection prior to PK sample collection.</description>
          </group>
          <group group_id="O3">
            <title>Octreotide LAR 30 mg</title>
            <description>Patients in this arm received Octreotide LAR 30 mg injection prior to PK sample collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Octreotide Trough Concentrations by Incident Dose</title>
          <description>Octreotide LAR trough concentrations by incident dose (last dose administered prior to PK sample collection). PK observations with missing concentrations, missing dose, missing elapsed time or an elapsed time from previous injection outside of 28±2 days window were excluded.</description>
          <population>PK analysis set: All patients with at least one LAR injection and one post-dose trough concentration data in core phase (up to month 12). No participants took the 30 mg dose in Months 1, 2 and 3, hence no data.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="153"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.86" spread="0.493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="139"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="0.280"/>
                    <measurement group_id="O2" value="1.21" spread="0.663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="134"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="0.107"/>
                    <measurement group_id="O2" value="1.29" spread="0.654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19">N/A = Insufficient number of participants to calculate standard deviation.</measurement>
                    <measurement group_id="O2" value="1.45" spread="0.653"/>
                    <measurement group_id="O3" value="1.55" spread="0.658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.65" spread="0.876"/>
                    <measurement group_id="O3" value="2.14" spread="1.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="0.754"/>
                    <measurement group_id="O2" value="1.58" spread="0.811"/>
                    <measurement group_id="O3" value="2.12" spread="0.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70">N/A = Insufficient number of participants to calculate standard deviation.</measurement>
                    <measurement group_id="O2" value="1.46" spread="0.704"/>
                    <measurement group_id="O3" value="2.14" spread="1.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.55" spread="0.727"/>
                    <measurement group_id="O3" value="2.16" spread="1.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.74" spread="1.013"/>
                    <measurement group_id="O3" value="2.20" spread="0.992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.66" spread="0.995"/>
                    <measurement group_id="O3" value="2.50" spread="1.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.74" spread="0.890"/>
                    <measurement group_id="O3" value="2.39" spread="1.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30">N/A = Insufficient number of participants to calculate standard deviation.</measurement>
                    <measurement group_id="O2" value="1.58" spread="0.695"/>
                    <measurement group_id="O3" value="2.55" spread="1.252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Reduction of Mean GH Level to &lt; 2.5μg/L and Normalization of IGF-1 After Crossover</title>
        <description>Percentage of participants with a reduction of mean GH levels to &lt; 2.5μg/L (based on a 5-point 2-hour profile) and normalization of sex- and age-adjusted IGF-1. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). Denominator for all time points is the Crossover Analysis Set (CAS).</description>
        <time_frame>Months 3, 6, 9, 12 after crossover</time_frame>
        <population>Crossover Analysis Set (CAS): All patients whose first dose in the extension is different from the first dose in the core.
Patients were analyzed according to the crossover treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Crossed Over to Pasireotide LAR (Extension)</title>
            <description>Includes data from the blinded extension phase (up to Month 26) collected after the crossover time point for patients who crossed over from Octreotide LAR treatment in the core to Pasireotide LAR treatment in the extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Crossed Over to Octreotide LAR (Extension)</title>
            <description>Includes data from the blinded extension phase (up to Month 26) collected after the crossover time point for patients who crossed over from Pasireotide LAR treatment in the core to Octreotide LAR treatment in the extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Reduction of Mean GH Level to &lt; 2.5μg/L and Normalization of IGF-1 After Crossover</title>
          <description>Percentage of participants with a reduction of mean GH levels to &lt; 2.5μg/L (based on a 5-point 2-hour profile) and normalization of sex- and age-adjusted IGF-1. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). Denominator for all time points is the Crossover Analysis Set (CAS).</description>
          <population>Crossover Analysis Set (CAS): All patients whose first dose in the extension is different from the first dose in the core.
Patients were analyzed according to the crossover treatment received.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M3 after crossover</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="9.8" upper_limit="27.3"/>
                    <measurement group_id="O2" value="2.6" lower_limit="0.1" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M6 after crossover</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" lower_limit="12.7" upper_limit="31.5"/>
                    <measurement group_id="O2" value="2.6" lower_limit="0.1" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M9 after crossover</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="13.7" upper_limit="32.8"/>
                    <measurement group_id="O2" value="5.3" lower_limit="0.6" upper_limit="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12 after crossover</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="9.8" upper_limit="27.3"/>
                    <measurement group_id="O2" value="0.0">N/A = For zero proportions, confidence intervals were not calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Reduction of Mean GH Level to &lt; 2.5μg/L</title>
        <description>Percentage of participants with a reduction of mean GH levels to &lt; 2.5μg/L (based on a 5-point 2-hour profile).
Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included). Denominator for time points up to Month 12 is the Full Analysis Set. Denominator for time points after Month 12 excludes patients who completed the core and did not enter the extension. Patients who discontinued were considered non-responders for the time points after discontinuation, patients who crossed over were considered non-responders for all time points after crossover.</description>
        <time_frame>Months 3, 6, 9, 12, 16, 19, 22, 25</time_frame>
        <population>Full Analysis Set: All patients who were randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Pasireotide LAR) as in the core. For patients who switched from blinded Pasireotide LAR to Octreotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
          <group group_id="O2">
            <title>Octreotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Octreotide LAR) as in the core. For patients who switched from blinded Octreotide LAR to Pasireotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Reduction of Mean GH Level to &lt; 2.5μg/L</title>
          <description>Percentage of participants with a reduction of mean GH levels to &lt; 2.5μg/L (based on a 5-point 2-hour profile).
Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included). Denominator for time points up to Month 12 is the Full Analysis Set. Denominator for time points after Month 12 excludes patients who completed the core and did not enter the extension. Patients who discontinued were considered non-responders for the time points after discontinuation, patients who crossed over were considered non-responders for all time points after crossover.</description>
          <population>Full Analysis Set: All patients who were randomized into the study.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4" lower_limit="41.8" upper_limit="57.1"/>
                    <measurement group_id="O2" value="43.4" lower_limit="36.1" upper_limit="50.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" lower_limit="37.9" upper_limit="53.1"/>
                    <measurement group_id="O2" value="47.8" lower_limit="40.4" upper_limit="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.6" lower_limit="35.2" upper_limit="50.3"/>
                    <measurement group_id="O2" value="46.2" lower_limit="38.8" upper_limit="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" lower_limit="35.8" upper_limit="50.8"/>
                    <measurement group_id="O2" value="47.3" lower_limit="39.8" upper_limit="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="25.8" upper_limit="41.6"/>
                    <measurement group_id="O2" value="22.2" lower_limit="15.9" upper_limit="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7" lower_limit="28.9" upper_limit="45.1"/>
                    <measurement group_id="O2" value="21.6" lower_limit="15.3" upper_limit="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" lower_limit="27.7" upper_limit="43.7"/>
                    <measurement group_id="O2" value="22.2" lower_limit="15.9" upper_limit="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" lower_limit="27.7" upper_limit="43.7"/>
                    <measurement group_id="O2" value="24.2" lower_limit="17.6" upper_limit="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Normalization of IGF-1</title>
        <description>Percentage of participants with normalization of sex- and age-adjusted IGF-1. Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included). Denominator for time points up to Month 12 is the FAS. Denominator for time points after Month 12 excludes patients who completed the core and did not enter the extension. Patients who discontinued were considered non-responders for the time points after discontinuation, patients who crossed over were considered non-responders for all time points after crossover.</description>
        <time_frame>Months 3, 6, 9, 12, 16, 19, 22, 25</time_frame>
        <population>Full Analysis Set: All patients who were randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Pasireotide LAR) as in the core. For patients who switched from blinded Pasireotide LAR to Octreotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
          <group group_id="O2">
            <title>Octreotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Octreotide LAR) as in the core. For patients who switched from blinded Octreotide LAR to Pasireotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Normalization of IGF-1</title>
          <description>Percentage of participants with normalization of sex- and age-adjusted IGF-1. Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included). Denominator for time points up to Month 12 is the FAS. Denominator for time points after Month 12 excludes patients who completed the core and did not enter the extension. Patients who discontinued were considered non-responders for the time points after discontinuation, patients who crossed over were considered non-responders for all time points after crossover.</description>
          <population>Full Analysis Set: All patients who were randomized into the study.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2" lower_limit="28.2" upper_limit="42.8"/>
                    <measurement group_id="O2" value="25.3" lower_limit="19.1" upper_limit="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8" lower_limit="28.7" upper_limit="43.4"/>
                    <measurement group_id="O2" value="24.2" lower_limit="18.1" upper_limit="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1" lower_limit="27.1" upper_limit="41.6"/>
                    <measurement group_id="O2" value="28.0" lower_limit="21.6" upper_limit="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8" lower_limit="28.7" upper_limit="43.4"/>
                    <measurement group_id="O2" value="22.0" lower_limit="16.2" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" lower_limit="22.7" upper_limit="38.0"/>
                    <measurement group_id="O2" value="13.7" lower_limit="8.7" upper_limit="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" lower_limit="18.4" upper_limit="33.0"/>
                    <measurement group_id="O2" value="15.7" lower_limit="10.3" upper_limit="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" lower_limit="19.0" upper_limit="33.7"/>
                    <measurement group_id="O2" value="17.0" lower_limit="11.4" upper_limit="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" lower_limit="19.0" upper_limit="33.7"/>
                    <measurement group_id="O2" value="14.4" lower_limit="9.2" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tumor Volume</title>
        <description>Percentage change from baseline in tumor volume (assessed by pituitary MRI). Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
        <time_frame>Baseline, months 6, 12, 19, 25</time_frame>
        <population>Full Analysis Set: All patients who were randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Pasireotide LAR) as in the core. For patients who switched from blinded Pasireotide LAR to Octreotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
          <group group_id="O2">
            <title>Octreotide LAR (Core &amp; Extension)</title>
            <description>Includes data from both blinded core and extension phase (up to Month 26) for patients who continued the same treatment (Octreotide LAR) as in the core. For patients who switched from blinded Octreotide LAR to Pasireotide LAR treatment in the extension, only data collected before crossover is included.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tumor Volume</title>
          <description>Percentage change from baseline in tumor volume (assessed by pituitary MRI). Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).</description>
          <population>Full Analysis Set: All patients who were randomized into the study.</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2420.7" spread="4159.21"/>
                    <measurement group_id="O2" value="2259.2" spread="3390.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1614.1" spread="2536.46"/>
                    <measurement group_id="O2" value="1565.4" spread="2245.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1482.4" spread="2387.88"/>
                    <measurement group_id="O2" value="1390.4" spread="2179.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="956.6" spread="1806.72"/>
                    <measurement group_id="O2" value="1009.9" spread="1578.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="840.4" spread="1706.07"/>
                    <measurement group_id="O2" value="814.1" spread="1306.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change at M6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="145"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.9" spread="21.73"/>
                    <measurement group_id="O2" value="-28.8" spread="20.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change at M12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.7" spread="21.83"/>
                    <measurement group_id="O2" value="-38.0" spread="24.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change at M19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.9" spread="22.81"/>
                    <measurement group_id="O2" value="-47.2" spread="24.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change at M25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.8" spread="20.81"/>
                    <measurement group_id="O2" value="-55.0" spread="21.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Reduction of Mean GH Level to &lt; 2.5μg/L After Crossover</title>
        <description>Percentage of participants with a reduction of mean GH levels to &lt; 2.5μg/L (based on a 5-point 2-hour profile). Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). Denominator for all time points is the Crossover Analysis Set (CAS).</description>
        <time_frame>Months 3, 6, 9, 12 after crossover</time_frame>
        <population>CAS: All patients whose first dose in the extension is different from the first dose in the core. Patients were analyzed according to the crossover treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Crossed Over to Pasireotide LAR (Extension)</title>
            <description>Includes data from the blinded extension phase (up to Month 26) collected after the crossover time point for patients who crossed over from Octreotide LAR treatment in the core to Pasireotide LAR treatment in the extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Crossed Over to Octreotide LAR (Extension)</title>
            <description>Includes data from the blinded extension phase (up to Month 26) collected after the crossover time point for patients who crossed over from Pasireotide LAR treatment in the core to Octreotide LAR treatment in the extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Reduction of Mean GH Level to &lt; 2.5μg/L After Crossover</title>
          <description>Percentage of participants with a reduction of mean GH levels to &lt; 2.5μg/L (based on a 5-point 2-hour profile). Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). Denominator for all time points is the Crossover Analysis Set (CAS).</description>
          <population>CAS: All patients whose first dose in the extension is different from the first dose in the core. Patients were analyzed according to the crossover treatment received.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M3 after crossover</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4" lower_limit="38.1" upper_limit="60.7"/>
                    <measurement group_id="O2" value="28.9" lower_limit="15.4" upper_limit="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M6 after crossover</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" lower_limit="32.2" upper_limit="54.7"/>
                    <measurement group_id="O2" value="31.6" lower_limit="17.5" upper_limit="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M9 after crossover</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3" lower_limit="42.9" upper_limit="65.4"/>
                    <measurement group_id="O2" value="31.6" lower_limit="17.5" upper_limit="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12 after crossover</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" lower_limit="33.4" upper_limit="55.9"/>
                    <measurement group_id="O2" value="23.7" lower_limit="11.4" upper_limit="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Normalization of IGF-1 After Crossover</title>
        <description>Percentage of participants with normalization of sex- and age-adjusted IGF-1. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). Denominator for all time points is the Crossover Analysis Set (CAS).</description>
        <time_frame>Months 3, 6, 9, 12 after crossover</time_frame>
        <population>CAS: All patients whose first dose in the extension is different from the first dose in the core. Patients were analyzed according to the crossover treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Crossed Over to Pasireotide LAR (Extension)</title>
            <description>Includes data from the blinded extension phase (up to Month 26) collected after the crossover time point for patients who crossed over from Octreotide LAR treatment in the core to Pasireotide LAR treatment in the extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Crossed Over to Octreotide LAR (Extension)</title>
            <description>Includes data from the blinded extension phase (up to Month 26) collected after the crossover time point for patients who crossed over from Pasireotide LAR treatment in the core to Octreotide LAR treatment in the extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Normalization of IGF-1 After Crossover</title>
          <description>Percentage of participants with normalization of sex- and age-adjusted IGF-1. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). Denominator for all time points is the Crossover Analysis Set (CAS).</description>
          <population>CAS: All patients whose first dose in the extension is different from the first dose in the core. Patients were analyzed according to the crossover treatment received.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M3 after crossover</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" lower_limit="11.7" upper_limit="30.1"/>
                    <measurement group_id="O2" value="7.9" lower_limit="1.7" upper_limit="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M6 after crossover</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9" lower_limit="21.1" upper_limit="42.1"/>
                    <measurement group_id="O2" value="7.9" lower_limit="1.7" upper_limit="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M9 after crossover</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" lower_limit="20.0" upper_limit="40.8"/>
                    <measurement group_id="O2" value="10.5" lower_limit="2.9" upper_limit="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12 after crossover</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" lower_limit="17.9" upper_limit="38.2"/>
                    <measurement group_id="O2" value="5.3" lower_limit="0.6" upper_limit="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Mean GH Values After Crossover</title>
        <description>Mean GH levels (based on a 5-point profile over 2 hours). Extension baseline was defined as last measurement prior to the start of crossover treatment. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over).</description>
        <time_frame>Extension baseline, months 3, 6, 9, 12 after crossover</time_frame>
        <population>CAS: All patients whose first dose in the extension is different from the first dose in the core. Patients were analyzed according to the crossover treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Crossed Over to Pasireotide LAR (Extension)</title>
            <description>Includes data from the blinded extension phase (up to Month 26) collected after the crossover time point for patients who crossed over from Octreotide LAR treatment in the core to Pasireotide LAR treatment in the extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Crossed Over to Octreotide LAR (Extension)</title>
            <description>Includes data from the blinded extension phase (up to Month 26) collected after the crossover time point for patients who crossed over from Pasireotide LAR treatment in the core to Octreotide LAR treatment in the extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Mean GH Values After Crossover</title>
          <description>Mean GH levels (based on a 5-point profile over 2 hours). Extension baseline was defined as last measurement prior to the start of crossover treatment. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over).</description>
          <population>CAS: All patients whose first dose in the extension is different from the first dose in the core. Patients were analyzed according to the crossover treatment received.</population>
          <units>μg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ext. Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="15.02"/>
                    <measurement group_id="O2" value="7.1" spread="9.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3 after crossover</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="19.70"/>
                    <measurement group_id="O2" value="9.8" spread="17.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M6 after crossover</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="14.51"/>
                    <measurement group_id="O2" value="9.8" spread="20.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M9 after crossover</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="3.03"/>
                    <measurement group_id="O2" value="8.7" spread="19.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12 after crossover</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.47"/>
                    <measurement group_id="O2" value="10.4" spread="26.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Extension Baseline in Tumor Volume After Crossover</title>
        <description>Percentage change from extension baseline in tumor volume (assessed by pituitary MRI).
Extension baseline was defined as last assessment prior to the administration of the new treatment after crossover. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over).</description>
        <time_frame>Extension baseline, months 6, 12 after crossover</time_frame>
        <population>CAS: All patients whose first dose in the extension is different from the first dose in the core. Patients were analyzed according to the crossover treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Crossed Over to Pasireotide LAR (Extension)</title>
            <description>Includes data from the blinded extension phase (up to Month 26) collected after the crossover time point for patients who crossed over from Octreotide LAR treatment in the core to Pasireotide LAR treatment in the extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Crossed Over to Octreotide LAR (Extension)</title>
            <description>Includes data from the blinded extension phase (up to Month 26) collected after the crossover time point for patients who crossed over from Pasireotide LAR treatment in the core to Octreotide LAR treatment in the extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Extension Baseline in Tumor Volume After Crossover</title>
          <description>Percentage change from extension baseline in tumor volume (assessed by pituitary MRI).
Extension baseline was defined as last assessment prior to the administration of the new treatment after crossover. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over).</description>
          <population>CAS: All patients whose first dose in the extension is different from the first dose in the core. Patients were analyzed according to the crossover treatment received.</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ext. Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1420.9" spread="1914.58"/>
                    <measurement group_id="O2" value="1809.6" spread="2579.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Value at M6 after crossover</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1027.5" spread="1282.42"/>
                    <measurement group_id="O2" value="1794.9" spread="2823.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change - M6 after crossover</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.1" spread="17.68"/>
                    <measurement group_id="O2" value="-12.3" spread="24.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Value at M12 after crossover</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="949.0" spread="1169.49"/>
                    <measurement group_id="O2" value="1610.4" spread="2666.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change - M12 after crossover</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.7" spread="25.20"/>
                    <measurement group_id="O2" value="-17.9" spread="27.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity Scores of Acromegaly Symptoms After Crossover</title>
        <description>Severity scores of acromegaly symptoms (Headache, Fatigue, Perspiration, Paresthesias, Osteoarthralgia).
Symptoms were scored from 0 (no symptom) to 4 (very severe). Extension baseline was defined as last measurement prior to the start of crossover treatment. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over).</description>
        <time_frame>Extension baseline, month 12 after crossover</time_frame>
        <population>CAS: All patients whose first dose in the extension is different from the first dose in the core. Patients were analyzed according to the crossover treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Crossed Over to Pasireotide LAR (Extension)</title>
            <description>Includes data from the blinded extension phase (up to Month 26) collected after the crossover time point for patients who crossed over from Octreotide LAR treatment in the core to Pasireotide LAR treatment in the extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Crossed Over to Octreotide LAR (Extension)</title>
            <description>Includes data from the blinded extension phase (up to Month 26) collected after the crossover time point for patients who crossed over from Pasireotide LAR treatment in the core to Octreotide LAR treatment in the extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Severity Scores of Acromegaly Symptoms After Crossover</title>
          <description>Severity scores of acromegaly symptoms (Headache, Fatigue, Perspiration, Paresthesias, Osteoarthralgia).
Symptoms were scored from 0 (no symptom) to 4 (very severe). Extension baseline was defined as last measurement prior to the start of crossover treatment. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over).</description>
          <population>CAS: All patients whose first dose in the extension is different from the first dose in the core. Patients were analyzed according to the crossover treatment received.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Headache: Ext. BL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.89"/>
                    <measurement group_id="O2" value="0.4" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: M12 after crossover</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.83"/>
                    <measurement group_id="O2" value="0.7" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Ext. BL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.07"/>
                    <measurement group_id="O2" value="0.7" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: M12 after crossover</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.91"/>
                    <measurement group_id="O2" value="0.7" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Perspiration: Ext. BL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.85"/>
                    <measurement group_id="O2" value="0.6" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Perspiration: M12 after crossover</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.98"/>
                    <measurement group_id="O2" value="0.5" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paresthesia: Ext. BL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.75"/>
                    <measurement group_id="O2" value="0.4" spread=".054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paresthesia: M12 after crossover</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.56"/>
                    <measurement group_id="O2" value="0.4" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteoarthralgia: Ext. BL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.91"/>
                    <measurement group_id="O2" value="0.6" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteoarthralgia: M12 after crossover</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.89"/>
                    <measurement group_id="O2" value="0.7" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ring Size After Crossover</title>
        <description>Ring size (based on jeweler’s finger gauge). Extension baseline was defined as last measurement prior to the start of crossover treatment. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). BL = baseline, LH = left hand, RH = right hand, CO = crossover</description>
        <time_frame>Extension baseline, month 12 after crossover</time_frame>
        <population>CAS: All patients whose first dose in the extension is different from the first dose in the core. Patients were analyzed according to the crossover treatment received. In the extension baseline, no participant had ring size on their right hand measured at the 5th digit, hence no data.</population>
        <group_list>
          <group group_id="O1">
            <title>Crossed Over to Pasireotide LAR (Extension)</title>
            <description>Includes data from the blinded extension phase (up to Month 26) collected after the crossover time point for patients who crossed over from Octreotide LAR treatment in the core to Pasireotide LAR treatment in the extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Crossed Over to Octreotide LAR (Extension)</title>
            <description>Includes data from the blinded extension phase (up to Month 26) collected after the crossover time point for patients who crossed over from Pasireotide LAR treatment in the core to Octreotide LAR treatment in the extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Ring Size After Crossover</title>
          <description>Ring size (based on jeweler’s finger gauge). Extension baseline was defined as last measurement prior to the start of crossover treatment. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). BL = baseline, LH = left hand, RH = right hand, CO = crossover</description>
          <population>CAS: All patients whose first dose in the extension is different from the first dose in the core. Patients were analyzed according to the crossover treatment received. In the extension baseline, no participant had ring size on their right hand measured at the 5th digit, hence no data.</population>
          <units>ring size</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ext. BL LH 4th digit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="2.10"/>
                    <measurement group_id="O2" value="11.0" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ext. BL LH 5th digit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="1.88"/>
                    <measurement group_id="O2" value="12.3" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ext. BL RH 4th digit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="2.42"/>
                    <measurement group_id="O2" value="12.4" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ext. BL RH 5th digit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12 after CO LH 4th digit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="2.27"/>
                    <measurement group_id="O2" value="11.2" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12 after CO LH 5th digit CO</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="2.14"/>
                    <measurement group_id="O2" value="12.5" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12 after CO RH 4th digit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="2.95"/>
                    <measurement group_id="O2" value="11.4" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12 after CO RH 5th digit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality-of-life as Measured by the AcroQoL Questionnaire After Crossover</title>
        <description>AcroQoL total scores. The AcroQoL questionnaire is unidimensional and contains 22 items divided in two scales: one that evaluates physical aspects (eight items) and another one that evaluates psychological aspects (14 items). The scoring of the questionnaire was performed as specified by the instrument developers. Extension baseline was defined as last measurement prior to the start of crossover treatment. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). Total scores range from 0 to 100. Higher scores represent better quality of life.</description>
        <time_frame>Extension baseline, months 12 after crossover</time_frame>
        <population>CAS: All patients whose first dose in the extension is different from the first dose in the core. Patients were analyzed according to the crossover treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Crossed Over to Pasireotide LAR (Extension)</title>
            <description>Includes data from the blinded extension phase (up to Month 26) collected after the crossover time point for patients who crossed over from Octreotide LAR treatment in the core to Pasireotide LAR treatment in the extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Crossed Over to Octreotide LAR (Extension)</title>
            <description>Includes data from the blinded extension phase (up to Month 26) collected after the crossover time point for patients who crossed over from Pasireotide LAR treatment in the core to Octreotide LAR treatment in the extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality-of-life as Measured by the AcroQoL Questionnaire After Crossover</title>
          <description>AcroQoL total scores. The AcroQoL questionnaire is unidimensional and contains 22 items divided in two scales: one that evaluates physical aspects (eight items) and another one that evaluates psychological aspects (14 items). The scoring of the questionnaire was performed as specified by the instrument developers. Extension baseline was defined as last measurement prior to the start of crossover treatment. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). Total scores range from 0 to 100. Higher scores represent better quality of life.</description>
          <population>CAS: All patients whose first dose in the extension is different from the first dose in the core. Patients were analyzed according to the crossover treatment received.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ext. Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.9" spread="23.11"/>
                    <measurement group_id="O2" value="59.8" spread="22.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12 after crossover</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.3" spread="24.34"/>
                    <measurement group_id="O2" value="61.2" spread="21.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Prolactin Levels After Crossover</title>
        <description>Prolactin (PRL) levels. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). Extension baseline was defined as last measurement prior to the start of crossover treatment.</description>
        <time_frame>Extension baseline, month 12 after crossover</time_frame>
        <population>CAS: All patients whose first dose in the extension is different from the first dose in the core. Patients were analyzed according to the crossover treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Crossed Over to Pasireotide LAR (Extension)</title>
            <description>Includes data from the blinded extension phase (up to Month 26) collected after the crossover time point for patients who crossed over from Octreotide LAR treatment in the core to Pasireotide LAR treatment in the extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Crossed Over to Octreotide LAR (Extension)</title>
            <description>Includes data from the blinded extension phase (up to Month 26) collected after the crossover time point for patients who crossed over from Pasireotide LAR treatment in the core to Octreotide LAR treatment in the extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Prolactin Levels After Crossover</title>
          <description>Prolactin (PRL) levels. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). Extension baseline was defined as last measurement prior to the start of crossover treatment.</description>
          <population>CAS: All patients whose first dose in the extension is different from the first dose in the core. Patients were analyzed according to the crossover treatment received.</population>
          <units>μg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ext. Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="18.42"/>
                    <measurement group_id="O2" value="15.7" spread="36.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12 after crossover</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="8.95"/>
                    <measurement group_id="O2" value="16.1" spread="25.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety Set (SS): all pts given drug with post baseline assessment. Pts analyzed as per treatment (trt) 1st received. 2 pts randomized to Oct. LAR who received Pas. LAR as 1st dose were included in Pas. grp.
Crossover Analysis Set (CAS): all pts with 1st dose in Ext. different from 1st dose in Core. Pts were analyzed acc. to crossover trt received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pasireotide LAR - up to 26 Months</title>
          <description>Includes data from both blinded core and extension phase (up to Month 26 cutoff date of 29-Dec-2011) for patients who continued the same treatment (Pasireotide LAR) as in the core. For patients who switched from blinded Pasireotide LAR to Octreotide LAR treatment, only data collected before crossover is included.</description>
        </group>
        <group group_id="E2">
          <title>Octreotide LAR - up to 26 Months</title>
          <description>Includes data from both blinded core and extension phase (up to Month 26 cutoff date of 29-Dec-2011) for patients who continued the same treatment (Octreotide LAR) as in the core. For patients who switched from blinded Octreotide LAR to Pasireotide LAR treatment, only data collected before crossover is included.</description>
        </group>
        <group group_id="E3">
          <title>Crossed Over to Pasireotide LAR - up to 26 Months</title>
          <description>Includes all data in the extension phase (up to 26-Month cutoff date of 29-Dec-2011) collected after the crossover time point for patients who crossed over from Octreotide LAR in the core to Pasireotide LAR treatment in the extension phase.</description>
        </group>
        <group group_id="E4">
          <title>Crossed Over to Octreotide LAR - up to 26 Months</title>
          <description>Includes all data in the extension phase (up to 26-Month cutoff date of 29-Dec-2011) collected after the crossover time point for patients who crossed over from Pasireotide LAR in the core to Octreotide LAR treatment in the extension phase.</description>
        </group>
        <group group_id="E5">
          <title>Pasireotide LAR - up to EOS</title>
          <description>Includes data from both core and extension phase (up to End-of-study date of 11-Mar-2016) for patients who continued the same treatment (Pasireotide LAR) as in the core. For patients who switched from blinded Pasireotide LAR to Octreotide LAR treatment, only data collected before crossover is included.
Per protocol, patients on Pasireotide LAR could continue to receive open-label Pasireotide LAR after treatment unblinding at Month 26, whereas those on Octreotide LAR were not followed after Month 26.</description>
        </group>
        <group group_id="E6">
          <title>Crossed Over to Pasireotide LAR - up to EOS</title>
          <description>Includes all data in the extension phase (up to End-of-study date of 11-Mar-2016) collected after the crossover time point for patients who crossed over from Octreotide LAR in the core to Pasireotide LAR treatment in the extension phase.
Per protocol, patients on Pasireotide LAR could continue to receive open-label Pasireotide LAR after treatment unblinding at Month 26, whereas those on Octreotide LAR were not followed after Month 26.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Acromegaly</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Toxic nodular goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Oesophageal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Concomitant disease progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hydrocholecystis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Kidney rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Post-traumatic neck syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Chondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Mixed hepatocellular cholangiocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Renal oncocytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Respiratory papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic hyperglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Catatonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic pigmented purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="170" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="76" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="72" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dilatation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="59" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Insulin-like growth factor decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="56" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pyelocaliectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

